CLDINYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as CLDWW

Calidi Biotherapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$0.78−0.05 (-6.40%)

Close on Oct 19, 2026

Market cap: $1.11M
P/E (TTM): –
Dividend yield: –

Calidi Biotherapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Revenue	–	–	–	0.05
Research & Development	9.74	8.88	13	7.26
Selling, General & Admin	11	13	16	16
Operating Expenses	20	22	29	23
Operating Income	-20	-22	-29	-23
Interest Expense	0.10	0.70	1.10	0.20
Other Non-Operating Income	0.19	-0.42	-0.21	-2.29
Legal Settlements	–	–	–	-1.62
Pretax Income	-20	-22	-29	-25
Income Tax Expense	0.02	0.01	0.02	0.01
Net Income incl. Noncontrolling Interests	-20	-22	-29	–
Minority Interest in Earnings	-0.16	-0.07	–	–
Net Income	-20	-22	-29	-25
Net Income to Common	-26	-24	-29	1.07
EPS (Basic)(per share)	-5.95	-35.70	-17.33	29.90
EPS (Diluted)(per share)	-5.95	-35.70	-17.33	29.90
Shares Outstanding (Basic, Weighted)(shares)	0.00	0.00	1.69	0.85
Shares Outstanding (Diluted, Weighted)(shares)	0.00	0.00	1.69	0.85
EBITDA	-19	-20	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -752.2%

Financial strength

Current ratio: 1.68
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 125.8%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.35
Dividend yield: –